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INTRODUCTION 
Periodontitis is a chronic inflammatory disease of the tooth supporting 
structures, resulting in the destruction of connective tissue and eventually 
tooth loss. Chronic inflammation is evoked as a result of the response to the 
microbial antigens present in the subgingival biofilm, its severity is modified 
by numerous host related factors such as environmental factors and genetic or 
epigenetic traits.
68
 
The inflammation begins as gingivitis before it progresses to involve 
the deeper structures of the periodontium. Gingival inflammation results in 
increased vascularity with more capillary loops, larger vessels, inflammation-
induced vasculitis and vascular permeability which allows lymphocytes and 
serum substances to gain access into the connective tissue and leads to a 
cascading immune response that results in tissue destruction.
125 
Early progression of periodontal disease shows disruption of the 
perivascular connective tissue followed by destruction of collagenous fibers, 
creating spaces within the tissue which is quickly filled up by inflammatory 
cells and loose connective tissue. The inflammatory cells like macrophages, 
monocytes and T cells at the site of tissue destruction release various 
cytokines and growth factors which upregulate or promote the process of 
angiogenesis.
64
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Angiogenesis is the growth of new blood vessels from the pre-existing 
vessels, which occurs in response to the presence of proangiogenic factors 
released from ischemic tissues, and in tissues that have increased metabolic 
process going on as in wound healing. The process has an important role in the 
etiology, progression and repair of tissues in various chronic inflammatory 
disease conditions. The formation of new vessels can perpetuate the chronic 
inflammatory process by the supply of oxygen and nutrients at the site of 
destruction.
66 
The process of angiogenesis involves dissolution of the basement 
membrane of the endothelial cells, rapid reproduction of new endothelial cells 
that stream out of the vessel wall in extended cords directed towards the 
source of the angiogenic factor.
32
 The cells in each cord continue to divide and 
eventfully fold over into tubes, which in turn connect up with other tubes 
budding from another donor vessel and form a capillary loop through which 
blood begins to flow. Later, smooth muscles cells eventually invade into the 
walls.
91 
The proangiogenic factors includes the vascular endothelial growth 
factor, epithelial cell growth factor, basic fibroblast growth factor, 
angiopoietins, transforming growth factor –α, β, hepatocyte growth factor, 
prostaglandin E2 , interleukin-8 etc.
91
 Many of these molecules are proteins that 
induce angiogenesis indirectly by stimulating the production of acidic or basic 
FGF and VEGF by macrophages and endothelial cells and direct inducers of 
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angiogenesis.
89
 These proangiogenic factors causes new vessels to sprout from 
either small venules or occasionally capillaries.
36
 Angiostatin, Endostatin  and 
Pigment epithelial derived factor are the most potent inhibitors of 
angiogenesis.
9,17,70 
In the gingival tissue, angiogenesis plays a vital role in both the 
maintenance of gingival health and development of periodontal diseases.  In 
chronic gingivitis, where alterations in tissue morphology is minimal and 
micro flora consist of predominantly gram-positive cocci and rods, the vessels 
subjacent to the lining epithelium of the gingival sulcus are only affected.
123
 In 
periodontitis, the gingival epithelium migrates apically and deepens its 
extensions into the underlying connective tissue, with subsequent loss of 
connective tissue of the periodontium.
87
 Thus in both the conditions disruption 
of vasculature takes place leading to accumulation of proangiogenic cytokines 
in the diseased site and the process of angiogenesis takes place leading to 
vascular remodeling and  maintenance of tissue homeostasis.
49
 Studies have 
also proved that bone formation and regeneration processes are closely linked 
to angiogenesis.
16,19 
The Angiopoietins have been identified in the mid1990s as a family of 
growth factors that are essential for blood vessel formation. There are four 
known members in the family so far. They are Angiopoietin1, Angiopoietin2, 
Angiopoietin3 and Angiopoietin4.
109
 Ang-1 acts as an agonist, whereas Ang-2 
is the antagonist. Ang-1 is primarily expressed by mesenchymal cell and acts 
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in a paracrine manner on the endothelium.  Ang 1 helps in mediating  vessel 
remodeling and maturation. Their biologic functions are endothelial cell 
sprouting and vessel stabilization.
6 
Ang 2 is expressed in regions of vascular remodeling under 
physiological and pathological conditions.
43,71 Ang-2 levels are upregulated in 
hypoxic conditions.
51,61,81,90 
They act via an internal autocrine loop 
mechanism.
33
 The biologic functions of Ang-2 are  migration of endothelial 
cells and proliferation of the endothelial cells.
69
 A few studies have identified 
and evaluated the presence and role of Ang1 and Ang2 in gingival 
inflammation, granulation lesions of the gingiva and periodontal disease 
conditions.
36
 Ang1 and Ang2 have been shown to modulate angiogenesis by 
both proangiogenic and anti angiogenic mechanisms.
123 
Hepatocyte growth factor also known as a pleiotropic cytokine, acts on 
epithelial cells in several organs 
55
 including the endothelial cells,
13
 βcells in 
the pancreas,
86
 and epithelium in the kidney
55
 and lungs.
120
  
 Studies   have   reported that periodontal fibroblasts secrete an HGF-
like chemoattractant for a gingival epithelial cell line, and hypothesized that 
HGF may be involved in epithelial invasion following the loss of connective 
tissue attachment in periodontitis.
83,84
 Studies by Ohshima et al. revealed  that 
the HGF level in GCF correlates well with clinical parameters of periodontal 
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disease, and suggest that HGF may be involved in epithelial invasion through 
its role as a scatter factor.
82
    
           Although the pivotal role of angiogenesis in chronic inflammation is 
well established, still insights into the molecular mechanisms involved in the 
process are few and yet to be unraveled. So this study aims to evaluate the 
gene expression of few angiogenic mediators like Ang1, Ang2 and HGF in 
periodontal health and disease. 
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AIMS AND OBJECTIVES 
 
The objectives of the present study are: 
1. To evaluate and compare the expression of angiopoietin-1, from 
gingival tissues in periodontal health and disease. 
2. To evaluate and compare the expression of angiopoietin-2, from 
gingival tissues in periodontal health and disease. 
3. To evaluate and compare the expression of hepatocyte growth factor, 
from gingival tissues in periodontal health and disease 
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REVIEW OF LITERATURE 
         Periodontitis is a chronic inflammatory disease affecting the tooth 
supporting structures which is initiated by the emergence of a pathogenic 
biofilm and is characterized by non-resolving inflammation. The disease 
progression is thought to be episodic in nature, with shorter periods of 
exacerbation followed by longer periods of remission.
102
  
The inflammatory response in periodontal disease results in increased 
vascularity with more capillary loops, larger vessels size and slowing of blood 
flow. Inflammation induced vasculitis and vascular permeability allows 
lymphocytes and serum substances to percolate into the connective tissue and 
leads to the events of tissue destruction.
68 
Vascular changes are important in both inflammation and repair of 
chronic diseases and blood flow plays a vital role in its resolution. 
Inflammation begins with vasodilation, increased vascular permeability, 
circulatory stagnation and diffusion of cells into the surrounding tissues 
resulting in tissue destruction.
22 
Angiogenesis refers to the growth and development of new capillary 
blood vessels from a pre-existing vasculature in response to external stimuli. 
Vasculogenesis is the development of new blood vessels which are required 
for many physiological processes like embryogenesis, wound healing and 
corpus luteus formation.
12 
The process of tissue regeneration and the repair of 
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wounds, cyclical proliferation of the nutrient-rich endometrium in preparation 
for implantation of the fertilized egg, and development of the embryo and its 
supporting tissues, is dependent on the rapid growth of new capillary blood 
vessels, known as "angiogenesis".
97
  
PHYSIOLOGIC ANGIOGENESIS: 
Physiologic Angiogenesis is the process of formation of new blood 
vessels from pre-existing vascular tissues, by two different mechanisms, such 
as the sprouting of new vessels from pre-existing vascular tubes or by the 
splitting of pre-existing vessels through intussusception angiogenesis (IA).
28 
The process of angiogenesis is initiated by quiescent endothelial cells 
(EC), which becomes activated by angiogenic signals (Pro-angiogenic 
factors). These activated ECs then alter the proteolytic balance of degradation 
of the basement membrane and promote the dissociation of pericytes from the 
capillaries. These ECs then proliferate and migrate towards the “tip-cells” 
(angiogenic stimulus).
31 
Finally tip cells fuses with cells from the neighboring 
sprout to generate connecting vessel loops.
16, 32, 89 
PATHOLOGICAL ANGIOGENESIS: 
The loss of endothelium’s quiescent state is a common feature of 
pathological condition. It is characterized by the failure of the resolution phase 
and by the generation of a highly disorganized vascular network. Molecules 
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that are shared by both angiogenic sprouting and the recruitment of 
inflammatory cells are likely to underlie the combinational processes.
5, 35, 37, 47 
Judah Folkman coined the term “Angiogenic Switch” describing the 
progression and the inhibition of angiogenesis by angiogenic stimulators and 
inhibitors.
40,41
 Pathological angiogenesis occurs in chronic diseases like 
Neoplasia, Vascular Malformations and Cardiovascular Disorders, Syndromes 
like Maffucci's Syndrome, Rendu-Osler-Weber Syndrome. It also plays a  vital 
role in Chronic Inflammatory Diseases and Aberrant Wound Repair conditions  
like  Diabetes, Hypertrophic scars, Non- healing fractures, Osteoradionecrosis, 
Psoriasis, Pyogenic granuloma, Rapidly progressing adult and juvenile 
periodontitis, Rheumatoid arthritis, Systemic sclerosis, Venus stasis ulcers.
77
  
PROCESS OF ANGIOGENESIS: 
The angiogenesis process is induced by so called stimulators, that 
exhibit chemotactic and mitogenic activity against epithelial cells, stimulating 
them to synthesize proteolytic enzymes (collagenase and plasminogen 
activator), thus leading to the basal membrane degradation, as well as enabling 
the migration of new epithelial cells, proliferation and differentiation of 
fibroblasts. These stimulators do also lead to formation of three-dimensional 
tubular structures, that will be turned into future blood vessels.
17, 56, 110, 121
  The 
following are the various types of angiogenic stimulators that take part in both 
types of angiogenesis.  
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 PRO-ANGIOGENIC MEDIATORS  
Adhesion molecules 
E-selectin 
VE-cadherin, PECAM (CD31) 
VCAM-1 
Cell surface antigens 
AC (CD) 133 
Chemokines 
Interleukin-8 (IL-8) 
Monocyte chemotactic protein-1 (MCP-1) 
Cyclooxgenase and related enzymes 
COX-2 
Nitric oxide synthase 
Developmental/specification signals 
Ephrins 
Id1/Id3 
Notch 
Review of Literature 
 
 
 
11 
 
Growth and differentiation signals 
Ang 1 & Tie2 
Endoglin & receptors 
Acidic and basic fibroblast growth factor (a and bFGF) 
Neuregulin/heregulin 
Platelet derived growth factor-BB (PDGF-BB) 
Scatter factor/hepatocyte growth factor/c-Met (SF/HGF) 
Transforming growth factor -β1 (TGF-β1) 
Tumor necrosis factor- α (TNF-α) 
Vascular endothelial growth factor family/VEGFR/ Neuropilins 
Hormones 
Leptin 
Integrins 
αVβ3 
αVβ5, 
α5β1 
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Proteinases 
Matrix metalloproteinases 
Plasminogen activators 
Plasminogen activator inhibitor type 1  
 ANGIOGENESIS INHIBITORS 
Ang 2 
Angiostatin 
Canstatin, proliferin-related protein, restin 
Endostatin 
Interferon (IFN)-α, β, γ, 
Inducible protein-10 (IP-10) 
Interleukin –4 (IL-4) 
Interleukin-12 (IL-12) 
Interleukin-18 (IL-18) 
Platelet Factor 4 
Prothrobin kringle 2 
Prolactin VGI 
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Osteopontin fragment 
Mapsin 
Meth-1, Meth-2 
Retinoids 
SPARC 
TIMPs, MMP inhibitors, PEX (MMP2 C terminal fragment) 
Thrombospondin-1 & -2 
Vasostatin.  
 ANGIOGENIC FACTORS:  
The vascular endothelial growth factor (VEGF) - VEGF is the most 
well-known and predominant member of angiogenesis. It was discovered by 
Abraham and Schilling in 1989 as endothelial cell specific mitogen.
45 
They 
are a family of 6 structurally related proteins that regulate the growth and 
differentiation of the vascular system. There are 4 major isoforms of VEGF 
coded by a different portion of the VEGF gene.
34 
Though these isoforms have 
identical characters, they differ in their ability to bind to the extra cellular 
matrix. The function of VEGF is that it stimulates vascular endothelial cell 
growth, survival and proliferation.
35
 VEGF stimulates cellular responses by 
binding to tyrosine kinase receptors on cell surface, causing them to dimerise 
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and becomes activated through transphosphorylation.  In preclinical models, 
VEGF has shown to facilitate survival of existing vessels, contributes to 
vascular abnormalities that may impede effective delivery of antitumor 
compounds and stimulate new growth. VEGF plays a crucial role in growth 
process.
5
 Blocking of VEGF signals by administrating soluble VEGF 
receptors resulted in suppression of blood vessel invasion into the bone growth 
plates with significant reduction in their length.
35 
Angiopoietins- Angiopoietin is part of a family of vascular growth 
factors that play a vital role in embryonic and postnatal angiogenesis.  They 
are paracrine growth factors. The Angiopoietin family includes four ligands –
Angiopoietin 1, Angiopoietin 2 and Angiopoietin 3/4 and two corresponding 
tyrosine kinase receptors -Tie1 and Tie2.
65
 Ang 1 acts in a paracrine agonistic 
manner inducing Tie2 phosphorylation and subsequent vessel stabilization.
23 
Ang 2 acts as an autocrine antagonist of Ang 1-mediated Tie2 activation.
33
 
Hence, Ang 2 primes the vascular endothelium to exogenous cytokines and 
induces vascular destabilization at higher concentrations.. The lesser known 
members of the family, Ang 3 and Ang 4, are orthologues found in mouse and 
human, respectively.
65
They have different tissue distributions: Ang 3 is 
expressed in multiple mouse tissues, whereas Ang 4 is specifically present at 
high levels only in human lungs. Ang 4 phosphorylates Tie2, whereas Ang 3 
not only fails to phosphorylate Tie2, but it even inhibits Ang 1-induced 
phosphorylation of Tie2 in human EC.
113 Studies have shown that Ang 3 and 4 
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are agonists of Tie2 receptor signaling, with Ang 3 being a specific ligand for 
Tie2 receptors of its own species.
64
   
Fibroblast growth factor (FGF): Fibroblast growth factors are a 
family of growth factors, involved in angiogenesis, wound healing, embryonic 
development and various endocrine signaling pathways.
92
 FGFs have a high 
affinity for heparan sulfate proteoglycans.
92 During embryonic development, 
FGFs have diverse roles in regulating cell proliferation, migration and 
differentiation.
77
 In the adult organism, FGFs are homeostatic factors and 
function in tissue repair and response to injury. Under abnormal conditions, 
some FGFs can attribute to the pathogenesis of cancer.
85
 There are 20 distinct 
FGF and four different tyrosine kinase receptors (FGFRs) .
92
 FGF-1 (acidic 
FGF) and FGF-2 (basic FGF) are part of the first growth factors that stimulate 
angiogenesis.  
        Hepatocyte growth factor (HGF): It’s a multifunctional cytokine 
involved in embryonic development and the repair and regeneration of various 
tissues /organs and their protection from injury. It is a protein secreted by 
fibroblasts and promotes matrix invasion of epithelial cells.
80
 They exhibit 
mitogenic and antiapoptotic activity.
64
 They enhance the mobility of different 
cell types, including the epithelial and vascular endothelial cells apart from the 
hepatocytes.
85
 Under inflammatory conditions they are expressed in 
mesenchymal cells whereas their receptors are found in the epithelial cells, 
endothelial cells, and progenitor cells.
41
  In endothelial cells and vascular 
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smooth muscle cells, HGF induces migration, proliferation and prevents cells 
from apoptosis.
73
  Several studies have shown that HGF is involved in the 
development of periodontal diseases. Their expression have been studied in 
GCF, saliva and tissues and they have correlated with the clinical 
parameters.
74 
ANGIOSTATIC FACTORS:   
Angiostatin is a specific endogeneous angiogenesis inhibitor produced 
in tumors. It inhibits primary and metastatic tumor growth by blocking tumor 
angiogenesis. It is derived from plasminogen spanning the first 4 kringle 
domains.
93
 Angiostatin suppresses proliferation, migration, differentiation, and 
tube formation of in vitro endothelial cells and potently inhibits 
angiogenesis.
70
 Systemic administration of angiostatin will induce 
mechanisms that consist of binding of the subunits of ATP synthase on the cell 
surface of endothelial cells which might inhibit proliferation and potently 
block neovascularization and growth of tumor metastasis.
116
  
       Endostatin was first identified from conditioned medium of a 
hemangioendothelioma cell line as a potent inhibitor of angiogenesis and 
tumor growth in vivo.
70 It  is a broad-spectrum angiogenesis inhibitor and may 
interfere with the pro-angiogenic action of growth factors such as basic 
fibroblast growth factor (FGF)  and vascular endothelial growth factor 
(VEGF).
119
 Endostatin also blocks migration and proliferation of endothelial 
cells and increases apoptosis.
10
  Endostatin interactions results in the 
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disruption of microfilaments and thereby facilitate to the inhibiting cell 
motility leading to angiostatic effect.
10,70
  
Pigment epithelium derived factor: Pigment epithelium-derived 
factor (PEDF) was first discovered by Joyce Tombran-Tink and Lincoln 
Johnson.
111
 They belong to the broadly expressed multifunctional member of 
the serine proteinase inhibitor (serpin) family. They play critical roles in 
neuroprotection, angiogenesis, fibrogenesis and inflammation. PEDF was 
originally isolated from the conditioned medium of cultured human fetal 
retinal pigment epithelial cells.
110 Dawson et al27 demonstrated PEDF as a 
potent endogenous anti-angiogenic factor PEDF levels were found to decline 
in angiogenic tissues/organs, in conditions such as the vitreous, aqueous 
humors and retinas of patients with proliferative diabetic retinopathy (DR) and 
in tumors of cancer patients.
103, 122 
THE ANGIOGENESIS CASCADE 
Angiogenesis occurs as an orderly cascade of molecular and cellular 
events in the wound bed:  
1. Endothelial cell surface has receptors to which angiogenic growth 
factors bind in preexisting venules (parent vessels); 
2. Growth factor-receptor binding activates signaling pathways within 
endothelial cells; 
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3. Proteolytic enzymes released by activated endothelial cells dissolve the 
basement membrane of surrounding parent vessels; 
4. Endothelial cells proliferate and sprout outward through the basement 
membrane; 
5. Endothelial cells migrate into the wound bed using integrins (αvβ3, 
αvβ5 and αvβ1) which are cell surface adhesion molecules; 
6. Matrix metalloproteinases (MMPs) dissolve the surrounding tissue 
matrix in the path of sprouting vessels; 
7. Vascular sprouts form tubular channels that connect to form vascular 
loops; 
8. Vascular loops differentiate into afferent (arterial) and efferent 
(venous) limbs; 
9. New blood vessels mature by recruiting mural cells (smooth muscle 
cells and pericytes) to stabilize the vascular architecture; 
10. Blood flow begins in the mature stable vessel.    
Angiogenesis in chronic diseases:  
"The angiogenic switch" is a term that implies the balance between 
angiogenic and angiostatic factors. Disturbance of this balance leads to a  
number of diseases
34
 that feature  the over proliferation of blood vessels 
consisting of hypertension, cancers, psoriasis, arthritis, diabetes, obesity, 
asthma,  atherosclerosis and other chronic inflammatory conditions.
1,57,124
 
Defect in angiogenesis also causes considerable heart brain ischemia, 
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neurodegeneration, hypertension, osteoporosis, respiratory distress, 
preeclampsia, endometriosis, postpartum cardiomyopathy, and ovarian 
hyperstimulation syndrome.
18 
Shoab et al. in 1999 stated that chronic venous stasis ulcer patients 
have elevated levels of VEGF in their circulation explaining the up regulation 
of angiogenic factors in hypoxic condition.
101
    
         AY Chong at al. in 2004 reported that Ang-2 levels were higher in 
acute Congestive Heart Failure (CHF) patients compared with chronic CHF.
24
      
            McCarty et al. in 2012 explained that in venous ulcers, the persistence 
of glomeruloid vessels may interfere with oxygen delivery and delay healing. 
In chronic venous stasis ulcers, high levels of proteases such as neutrophil 
elastase, MMPs and urokinase‑type plasminogen activator are upregulated.75  
Weinheimer‑Haus et al. in 2014 reported that low intensity 
vibrations may exert beneficial effects on wound healing by enhancing 
angiogenesis and granulation tissue formation, and these changes are 
associated with an increase in pro‑angiogenic growth factors.116 
          Peripheral arterial disease (PAD) results in severe ischemia. Reduced 
tissue perfusion due to ischemia results in progressive tissue hypoxia, 
ischemia, necrosis and skin damage. According to literature, tissue hypoxia 
should initiate angiogenesis through an activated HIF‑1α and angiogenic 
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growth factors. Konya et al 2014 reported that patients with PAD, had 
elevated serum levels of hepatocyte growth factor than in normal subjects thus 
substantiating the literature.
63
  
ROLE OF ANGIOGENESIS IN PERIODONTAL DISEASE AND 
SURGERY: 
Angiogenesis takes place both in the maintenance of gingival health 
and development of chronic inflammatory disease.  
The development of a vascular system at the injury site enable pro 
inflammatory cells to be transported to the lesion, supply oxygen and nutrients 
and remove the cellular debris from inflamed tissues.
63 
To complement this 
there is an increase in the potential substrate, for the production of cytokines, 
adhesion molecules and further progression factors for inflammation.
52
   
Johnson et al in 1999 demonstrated the effect of VEGF to be a factor 
in initiation and progression of gingivitis to periodontitis, possibly by 
promoting expansion of the vascular network coincident to progression of the 
inflammation.
53
    
Yuan et al in 2000 was the first to demonstrate the expression of    
Ang 1 and Ang 2 proteins in the cytoplasm of macrophages-like mesenchymal 
cells and smooth muscle cells by immunohistochemistry in pyogenic 
granuloma along with other vascular morphogenic factors.
123 
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Lakey et al. in 2000 explained the importance of angiogenesis in 
tissue repair and explained the therapeutic implications of angiogenesis on 
periodontal surgery for wound healing .
64  
Uzel et al in 2001 conducted a semiquantitative analyses on 
phenytoin induced gingival overgrowth tissues and suggested a possible role 
of proangiogenic factor FGF in promoting the development of fibrotic lesions 
in phenytoin-induced gingival overgrowth.112 
Byun et al. in 2007 explained that  the expression patterns of VEGF 
and its receptors  plays an important role in osteogenesis, and that osteoblasts 
and immature fibroblast-like cells of the distracted bone may have an 
autocrine growth effect during distraction osteogenesis.
14   
Suzuki et al. in 2011 stated that dental pulp stem/progenitor cells can 
be induced to migrate by chemotactic cytokines and act as endogenous cell 
sources for regeneration and mineralization.
107
   
Aspriello et al. in 2011 compared the effects of enamel matrix 
derivative and the VEGF on gingival tissues in chronic periodontitis patients. 
He showed a statistically significant upregulated effect of VEGF on the 
gingival tissues of periodontal pockets than enamel matrix derivative 
component.
3   
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THE ANGIOPOIETIN FAMILY:  
          Davis in 1996   discovered the   first member of the angiopoietin 
family, Ang 1, by   its ability to bind Tie2 extracellular domain.
26
 Later, 
Valenzuela et al in 1999 demonstarted that low expressions of angiopoietins 
were used to clone Ang 2, 3 and 4.
113
 The angiopoietins share a similar overall 
structure with a short amino-terminal motif followed by a coiled-coil domain 
and carboxy-terminal fibrinogen-like domains. The Angiopoietins are secreted 
glycoproteins with a dimeric molecular weight of approximately 75 kDa. Ang 
1 has 498 aa and is located on chromosome 8q22.
4 
 Ang 2 has 496 aa and is 
located on chromosome 8q23.
4
 Both Ang 1 and Ang 2 molecules show 
sequence homology of about 60% in human beings.
32
  
Hanahan D in 1997 proposed that the pattern of expression and 
regulation of Ang 1 and Ang 2 is consistent with the concept that Ang 1 
provides a constitutive tonic signal to promote quiescence of the endothelium 
and this is modified by the more actively regulated antagonist Ang 2.
49
     
  .  Stratmann in 1998 explained Ang 2 expression occurs in areas of 
endothelial activation and angiogenesis, like in ovary and tumor vessel 
endothelia where it coincides with vessel destabilization during 
angiogenesis.
105
             
Studies by Partanen et al. in 1999 described Ang 1 as widely 
expressed and is present in periendothelial cells in quiescent vasculature.
88
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           Gravallese in 2003 demonstrated that Ang 1 is also involved in 
inflammatory diseases. Synovial fibroblasts are a key player during 
inflammatory diseases and they are a major source of Ang 1.
47 
            Fiedler in 2004 stated that Ang 2 expressed in endothelium is stored 
within Weibel-Palade bodies and rapidly released following stimulation with 
thrombin and other agonists.
39 
           Witzenbichler in 2005 stated that Ang 1 acts as an anti-inflammatory 
cytokine and protects against endotoxic shock-induced by LPS and thereby 
prevent microvascular leakage.
118 
           Scott in 2005 explained that Ang 1   is also upregulated during 
diseases by inflammation promoting cytokines, including TNF-a via the NF-
kappa B signaling pathway
 
.
100
   
           Colton 2010 stated that during chronic inflammation, the Ang–Tie 
system is involved in   process expands the region of the vasculature in which 
vessel leakage and leukocyte emigration occurs.
20 
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ANGIOPOIETIN RECEPTORS:  
Tie2  
          Ang 1 binds and signals through the receptor tyrosine kinase Tie2.
20
 
This receptor and its close relative Tie1 share a similar structure with an 
extracellular domain of an immunoglobulin (Ig)-like motif followed by three 
EGF-homology domains a second Ig motif and three fibronectin type III 
repeats.
29 
The amino acid sequence identity between Tie1 and Tie2 
intracellular domains is 76%.
96
  
Tie1 & Integrins:    
Studies by Carlson 2001, explained that stable expression of the 
human α5 integrin subunit in these cells rescued adhesion to Ang 1 and 
promoted an increase in adhesion to Ang 2. He also suggested that Ang 1 and 
Ang 2 can directly support cell adhesion mediated by integrins.
15  
        Dallabrida in 2005 showed that Angiopoietin 1 limits ischemia-
induced cardiac injury by blocking antibodies. Further Angiopoietin 1 may 
prove therapeutically valuable in cardiac remodeling by supporting myocyte 
viability and preserving pump function.
25 
        Weber in 2005 showed that the isolated receptor-binding domain of    
Ang 1 is capable of mediating effects on full-length Ang 1 independently of 
Tie2 phosphorylation, possibly through integrin ligation.
114
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           Recent studies by Saharinen in 2009 indicate that, Ang family 
members may signal through Tie1. Ang 1 can induce Tie1 phosphorylation in 
endothelial cells.
97 
 It is likely that either the ligand interacts with Tie1 to 
induce activation, or that it activates Tie1 indirectly via another Ang 1 
receptor.
21
 The mechanism of action of this is still unclear. Therefore, Ang 2 
appears to antagonize the effects of Ang 1 on Tie1 phosphorylation. Thus, 
Ang 2 could act to limit Ang 1 signaling through Tie1 as it does with Tie2.
30
   
CELLULAR EFFECTS AND SIGNALLING OF ANGIOPOIETIN   
The steps involved in the cellular and signaling mechanism of Ang 1 and   
Ang 2 are   
• Apoptosis   
• Migration  
• Reorganization  
• Proliferation  
• Inflammatory gene expression   
• Permeability  
• Hematopoiesis  
• Putative signaling from Tie1 and integrins.    
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          Studies by Rossant 1995 with Tie1 gene targeted mice have shown 
that in vivo, Tie1 is required cell for endothelial cell survival during late 
embryogenesis.
94, 99
 Thus it is likely that Tie1 has a role in suppression of 
endothelial apoptosis, possibly via the PI3K pathway.
20
           
Hashiyama &Ohshiro 1996, explained the presence of  
Hematopoietic progenitor cells
50,8
  and  their consistency  with  hematopoiesis, 
the Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence 
in the bone marrow niche.
2
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Ang 1 
P13K and adapter protein Dok-R 
Tie2 
PTB (phosphorylated Y1108) 
PH (P13K dependent) 
Increased endothelial mobility 
GTPase 
Activation of ANGIOPOIEITIN induced endothelial activity. 
                  Hansbury 2001, explained Ang 1- stimulated reorganization of 
endothelial tubules and invasion into matrices is not seen in endothelial cells 
lacking Tie2
61
 but can be stimulated by a Tie2-activating antibody in the 
rats.
49
 Consistent with such remodeling effects, Ang 1 stimulates production of 
proteases including plasmin and matrix metalloproteases, as well as 
suppressing secretion of tissue inhibitor of metalloprotease-2.
58
 The inhibitors 
and dominant-negative constructs has indicated a number of signaling 
intermediates involved in Ang 1-induced re-organization of endothelium and 
motility, including PI3K, the adaptor protein ShcA, focal adhesion kinase and 
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endothelial nitric oxide synthase.
4,6,23,58
 Additional growth factors may be 
necessary for Ang 1 to induce endothelial proliferation.  
An important cellular effect of Ang 1 is its ability to improve integrity 
of endothelial monolayers. The ligand augments integrity of unstimulated 
monolayers and counteracts the increased permeability following activation 
with thrombin, VEGF or TNFα.43, 98 Yet again, the signalling mechanisms 
mediating these effects have yet to be delineated.  
The vascular protective effects of angiopoietins have been found to 
promote blood vessel survival, inhibit vascular leakage and suppress vessel 
inflammation.
11
    
            Lester et al. in 2009 revealed that lower concentrations of Ang 1 
within inflamed gingiva compared to healthy gingiva, suggest that Ang 1 may 
be a factor determining the severity of periodontal disease, he strongly 
explains that   there is a significant negative correlation between the severity 
of gingival inflammation and Ang 1 concentrations in diseased sites.
66 
Hepatocyte growth factor also known as scatter factor (SF) is a 
heterodimeric protein secreted by cells of the mesodermal origin. HGF was 
first described by Stoker and Perryman
104
 as a secretory product of 
fibroblast which dissociates epithelial cells, thereby increasing their motility 
and invasiveness. HGF causes spread of the epithelial cells and hence also 
known as scatter factor. Weidner further reveled that SF and HGF are 
identical.
115
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HGF affects nervous system, immune system and reticuloendothelial 
system. It induces a spectrum of biological activities in epithelial cells, 
inducing mitogenesis, stimulation of cell motility and the promotion of matrix 
invasion and is a potent angiogenic factor.
79
 It acts as a mitogen, motogen, 
morphogen, anti-apoptotic factor, and scatter factor for various kinds of 
epithelial cells.
73
 It is a protein secreted by mesenchymal cells such as 
fibroblasts, and promotes motility and matrix invasion of epithelial cells.
85
 
 
HGF is produced by mesenchymal cells such as fibroblasts, 
macrophages, smooth muscle cells, endothelial cells and the fat storing cells in 
the liver. The tissues that contain HGF protein are blood cells (monocytes, 
leukocytes and platelets), liver, lungs, brain, bone marrow, spleen and 
placenta. HGF has a molecular weight of 84 kDa.
114
  
 
Structure and biological function of HGF 
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 Production and activation of HGF:   
HGF is produced and secreted as a pro-HGF by stromal cells such as 
fibroblasts, macrophages, renal mesangium and so on. Secreted pro-HGF is 
cleaved at Arg and Val by HGF-activators, such as urokinase-type 
plasminogen activator (uPA).
85
 Multi-faceted biological actions of HGF are 
mediated via the c-Met/HGF-receptor. Binding of HGF to c-Met leads to 
tyrosine phosphorylation, and each biological activity is elicited via the 
recruitment of down-stream adaptor molecules.
114 
HGF is a pluripotential regenerative cytokine – it is a key factor in the 
pathogenesis and progression of periodontal disease, mostly through its over-
stimulation of gingival epithelial cell growth and impairment of the 
regeneration of collagenous structures.
73
   
HGF in periodontal disease:    
Studies by Ohshima et al, 2001 showed that periodontal ligament 
fibroblast and gingival fibroblast secrete an HGF- like factor, and suggested 
that such a factor derived from periodontal fibroblasts might play a role in 
epithelial apical migration in periodontitis.
82
    
Studies by Otsuka K 2002, showed that the HGF level correlated 
positively with PD and GI, and was significantly higher in specimens from 
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BOP-positive sites and those where PD exceeded 4 mm compared with those 
from sites that were BOP-negative or with a PD less than 3 mm.
83
     
Mitsuhiro et al, 2002, suggested that synergistic expression of HGF 
and HGFA in gingiva may indicate a high risk for epithelial down growth 
followed by loss of connective tissue attachment without inflammatory cell 
infiltrate.
84 
In 2003, Ohshima et al also suggested that, elevated levels of HGF in 
GCF may reflect disease progression, specifically loss of connective tissue 
attachment followed by epithelial invasion and bone resorption.
85 
Magdalena et al 2006 proved that the salivary HGF concentration in 
patients with periodontal disease required treatment almost 3 times higher than 
in healthy subjects. They further suggested that salivary HGF was a novel 
potential marker for early and symptomatic periodontal disease.
117 
Nagaraja, Pradeep et al 2007 proposed that HGF concentration 
increased proportionally with the progression of periodontal disease, and HGF 
concentrations showed a positive correlation with the clinical parameters, 
suggesting that HGF plays a key role in periodontal disease progression. Also, 
following non-surgical periodontal therapy, the levels of HGF decrease 
significantly suggesting that HGF could be useful for monitoring the response 
to periodontal therapy.
78
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Rudrakshi et al 2011 in a study demonstrated a significant correlation 
in the levels of HGF in GCF and in saliva of patients with and without chronic 
periodontitis. The results also indicated that the HGF levels in GCF and saliva 
correlated well with the clinical parameters and with the severity of the 
periodontal disease.
95 
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MATERIALS AND METHODS 
Twenty patients who reported to the Outpatient Department of 
Periodontics, Ragas Dental College, Chennai were recruited in the study. 
Patients were divided into two groups based on their periodontal health status. 
Informed written consent was obtained from all the patients. The patients were 
informed that this research work was in no way directly related to the therapy 
or cure of the disease. The study was undertaken following approval from the 
Institutional Review Board. 
STUDY POPULATION / INCLUSION CRITERIA: 
The subjects were divided into two groups: 
Group A: Healthy subjects (Control group) who had Probing Depth <3mm 
with no clinical attachment loss, Bleeding on Probing <10%. 
Group B: Advanced chronic periodontitis patient (Test group) who had 
Probing Depth ≥6 mm, Clinical attachment loss ≥5mm with bleeding on 
probing. 
EXCLUSION CRITERIA: 
 Patients with history of periodontal therapy or antibiotic therapy in the 
past 6 months. 
 Patients with history of systemic diseases that may affect the 
periodontal status. 
 Pregnancy and Lactation. 
 Smokers. 
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SAMPLE COLLECTION: 
Gingival sample: 
Healthy tissue samples were obtained from patients who had reported 
to the department for crown lengthening procedure. Diseased tissue samples 
were obtained from patients who underwent modified Widman surgery for 
advanced periodontitis. Tissue samples were thoroughly washed with PBS 
(Phosphate buffered saline) and stored in RNAase inhibitor at -20°C until 
further RNA extraction is carried out. 
TOTAL RNA EXTRACTION 
Isolation of total RNA:  
Total RNA was isolated from health and diseased cells by using total 
RNA isolation reagent (Swift tissue RNA) kit.  
REAGENTS: 
1. Swift tissue RNA Kit(Buffer SL, Buffer SE) 
2. β-Mercaptoethanol 
3. 70% ethanol  
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Procedure:  
600µl of buffer SL was taken in a 1.5ml tube. 6µl of                                       
β-mercaptoethanol was added and vortexed. Approximately, the volume of 
buffer SL and β-ME (1%) has been increased for larger volume of sample. 
Tissue sample of about 20-30mg was added and homogenized using tissue 
lyseror by plastic pestle. The homogenized mixture was centrifuged at 
13,400rpm for 15mins. 350µl of the clear supernatant was pipetted out into a 
1.5ml tube and equal volume of 70% ethanol (350µl) was mixed to the content 
for binding. 600µl of the lysate was then centrifuged at 10,000rpm for 15secs. 
The flow through was discarded and the SMS column was backed with the 
collection tube. 600µl of 70% ethanol was added to the SMS column and 
centrifuged at 10,000rpm for 15secs and the column was washed. The flow 
through was then discarded. The wash step was repeated one more time to 
improve the quality of RNA. The collection tube was then centrifuged for 
2mins at 13,400rpm to remove the residual ethanol. It was then transferred to a 
new 1.5ml tube and 50-100µl of buffer SE was added on the membrane and 
incubated for 1min. The tubes were centrifuged at 13,400rpm for 1min. Tissue 
RNA was collected at the bottom of the tube. The collected RNA was stored at 
-20C.  
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QUANTIFICATION OF RNA 
The RNA pattern obtained by above mentioned method was clear as 
expected and was observed by spectrophotometric readings i.e., absorbance 
ratio at 260 and 280nm in a Nanodrop instrument (Thermoscientific Inc). 
QUANTITATIVE RT-PCR ANALYSIS OF Ang 1 & Ang 2,  
AND HGF EXPRESSION: 
Principle 
Real time-PCR selectively amplifies the first strand of cDNA that has 
been synthesized in vitro by RNA polymerase from mRNA templates by 
reverse transcription. The cDNA is first denatured by heating in the presence 
of a large molar of two oligonucleotide primers and the four dNTPs. The 
reaction mixture is then cooled to a temperature that allows the 
oligonucleotide primers to anneal to their target sequences, after which the 
annealed primers are extended with DNA polymerases. The cycle of 
denaturation, annealing and DNA synthesis is then repeated many times. Real-
time experiments monitor and report the accumulation of PCR product, as 
detected by increased fluorescence, during thermal cycling. Data collection 
during the early exponential phase of PCR allows the software to accurately 
calculate initial template quantities. 
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First strand cDNA synthesis 
The first step in RT-PCR is the reverse transcription of total RNA to a 
single stranded complementary DNA (cDNA) which was done using Helini 
cDNA Synthesis Kit (HELINI biomolecules). 
Helini cDNA Synthesis Kit: 
 OligodT Primer Mix 
 Random hexamer enzyme mix 
 cDNA reaction mix 
Quantitative RT-PCR - SYBR® Premix Ex Taq
TM
 II kit (Tli RNaseH 
Plus): 
Kit Components:  
1. SYBR Premix Ex Taq II (Tli RNaseH Plus) (2X) 1 ml x 5    -HS DNA 
Polymerase, dNTP mixture, Mg2+, Tli RNaseH, and SYBR Green I. 
2. ROX Reference Dye (50X) 200 μl  
3. ROX Reference Dye II (50X) 200 μl 
Real Time-PCR was carried out on Mastercycler realplex 
quantitative PCR system (Eppendorf). Reaction was performed using 5.0 μl 
of 2X reaction buffer, 1μl of 100 nM of both forward and reverse primers of 
gene of interest, 1 μl of forward and reverse primers of GAPDH, 3.0 μl of 
diluted cDNA was made upto a 10μl reaction. The thermal cycling protocol 
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was as follows: 95ºC for 5 minutes, followed by 40 cycles of PCR at 95ºC for 
30 seconds and 58ºC for 30 seconds. All reactions were performed in triplicate 
along with no template control (NTC). Melt curve analysis was performed 
using the thermal cycling programmed at 50ºC - 95ºC for each sample to 
determine the presence of multiple amplicons, nonspecific products, and 
contaminants. The relative amount of mRNA was calculated by using the 
comparative Ct method.    
Primer sequences:   
Angiopoietin 1  
F: 5’ TAACAGGAGGATGGTGGTTTG 3’         
R: 3’ AACTGGGCCCTTTGAAGTAG 5’ 
Angiopoietin 2 
F: 5’ ATCAGGACACACCACGAATG 3’ 
R: 3’ CATCCTCACGTCGCTGAATAA 5’  
 HGF  
F: 5’ CACGACAGTGTTTCCCTTCT 3’ 
R: 3’ CTGATCCTTCAGGGCCATATAC 5’  
GAPDH  
F: 5’ GGTGTGAACCATGAGAAGTATGA 3’ 
R: 3’ GAGTCCTTCCACGATACCAAAG 5’  
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DATA INTERPRETATION 
The values obtained in the Real time-RT PCR were interpreted using 
the formula of fold change, 
2
-ΔΔct
 = [ct of gene of interest – ct of internal control] of disease sample – 
[ct of gene of interest – ct of internal control] of health sample. 
This form of equation may be used to compare the gene expression in 
two different samples (health and disease). Each sample is related to an 
internal control gene.  
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                                               INFORMED CONSENT  
                                      DEPARTMENT OF PERIODONTICS 
1) NAME: 
2) AGE & SEX: 
3) OCCUPATION: 
4) INCOME: 
5) ADDRESS: 
6) CONTACT NO: 
7) BIOPSY: 
            a) Type: 
            b) Nature of specimen: 
8) CLINICAL DETAILS: 
            a) Site: 
           b) Colour: 
          c) Consistency: 
          d) Size: 
9) PROVISIONAL DIAGNOSIS: 
10) PATIENT CONSENT:  
I have been informed about the surgical procedure for removal of 
gingival tissue while performing periodontal surgery that will not have any 
determined effect on my healing soft tissue. The tissue obtained will be used 
for research purpose only, the result which will be informed to my request. I 
henceforth give my consent for the above procedure.  
 
PATIENT      SIGN                                                                                         
DOCTOR SIGN                                                       HOD SIGN 
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                                            CASE HISTORY PROFORMA  
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STATISTICAL ANALYSIS 
  All statistical analysis were performed using Statistical Package for 
Social Service (SPSS, Version 17 for Microsoft windows).  
The data between Ang 1, Ang 2 & HGF in health and disease were 
normally distributed and therefore parametric tests were performed. The test 
chosen was independent sample student T test to evaluate the difference 
between the Ang 1, Ang 2 & HGF in periodontal healthy and disease groups. 
A two sided p value of <0.05 was considered to be statistically significant. 
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Fig 6: SWIFT RNA ISOLATION KIT 
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RESULTS 
Gingival samples were obtained from 10 patients from each of 
periodontally healthy and diseased groups and total RNA isolated and 
extracted. The purity of the extracted RNA was analyzed with a NANO Gel 
electrophoresis system and cDNA conversion was done. The mRNA 
expression for Ang 1, Ang 2 and HGF was evaluated by using real time                 
RT-PCR.  
The results of the present study are presented in the Tables- 1, 2, 3. 
The data obtained was interpreted using the formula of fold change  
2
-ΔΔct
 = (ct of gene of interest – ct internal control) of disease sample –               
(ct of gene of interest – ct internal control) of health sample. 
Ang 1:   
         The results have shown that the mean ct value of Ang 1 in the disease 
group was 32.37 and that of GAPDH was 25.60. The mean delta ct (Δct) value 
in the disease group was 6.725±2.68. The mean ct value of Ang 1 in health 
was 33.76 and that of GAPDH was 23.40. The mean Δct of Ang 1 in health 
was 10.40±1.39. The individual ct values of Ang 1 in disease and health over 
the control and the individual Δct values of the samples are summarized in 
Table 1a.  
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The fold change was derived using the above mentioned formula. The 
fold change of Ang 1 in disease over health was obtained as 3.68. The result 
showed an upregulation of Ang 1 gene in diseased samples when compared to 
health. The mean fold change of Ang1 over control is tabulated in Table 1b 
and depicted in Graph 1.    
          Independent sample T test was performed to compare the fold change 
of Ang1 in health and disease and was found to be statistically insignificant at 
p = 0.129(p > 0.05).The statistical analysis are tabulated in Table 1c.  
Ang 2:   
The results have shown that the mean ct values of Ang 2 in the disease 
group was 31.54 and that of GAPDH was 23.85. The mean delta ct (Δct) value 
in the disease group was 7.683±3.31. The mean ct value of Ang 2 in health 
was 30.17 and that of GAPDH was 23.58. The mean Δct of Ang 1 in health 
was 6.592±3.94. The individual ct values of Ang 2 in disease and health over 
the control and the individual Δct values of the samples are summarized in 
Table 2a.  
The fold change of Ang 2 in disease over health was -1.09 This shows 
that there was a down regulation of Ang 2 in disease when compared to health. 
The mean fold change of Ang 2 over control is tabulated in Table 2b and 
depicted in Graph 2.       
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Statistical analysis was performed using independent sample T test  to 
compare the fold change of Ang2 in health and disease and  was found to be 
statistically insignificant at p-value =0.934 (p-value is >0.05).The tabulations 
are presented in table 2c.   
 HGF :  
The results shows that the mean ct values of HGF in the disease group 
was 29.08 and that of GAPDH was 24.18. The mean delta ct (Δct) value in the 
disease group was 4.898±3.72. The mean ct value of HGF in health was 29.96 
and that of GAPDH was 23.5. The mean Δct of HGF in health was 
6.473±3.01. The individual ct value and Δct value of HGF in health and 
disease are summarized in Table 3a.  
 The fold change of HGF in disease over health was 1.574. This shows 
that there was a up regulation of HGF in disease when compared to health. 
The fold change of HGF over control is tabulated in Table 3b and depicted in 
Graph 3.   
 An independent sample T test was performed to compare the fold 
change of HGF in health and disease and was found to be not statistically 
significant with a p-value of 0.899 (p-value is >0.05). The statistical analysis 
are detailed in Table 3c. 
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Table:1a- Relative expression of Ang 1 in health and disease 
 
 
 
 
 
 
 
 
 
 
 
GROUP ct Ang 1 ct GAPDH Δct MEAN ct 
  
  
  
  
HEALTH 
NA 23.50 NA  
 
 
 
 
10.401 
35.09 25.50 9.58 
34.38 25.14 9.24 
33.30 22.50 10.8 
NA 24.34 NA 
35.15 23.57 11.57 
33.19 22.05 11.14 
31.5 21.68 9.81 
NA 23.22 NA 
NA 24.75 NA 
GROUP ct Ang 1 ct GAPDH Δct MEAN ct 
  
  
  
  
DISEASED 
29.2 18.75 10.45  
 
 
 
6.725 
32.82 31.45 1.37 
34.66 25.29 9.37 
32.1 25.95 6.14 
25.99 24.51 1.47 
33.35 24.74 8.60 
37.93 30.05 7.88 
NA 24.15 NA 
34.06 26.19 7.86 
31.28 23.89 7.39 
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Table:1b- Fold change of Ang 1  in disease over health 
  
  
  
  
  
 
Tables: 1c- Statistical  analysis of Ang 1 
 
 
 
 
 
 
 
 
 
GROUP MEAN Δct FOLD 
CHANGE 
DISEASE 6.725±2.86 
3.68 
HEALTH 10.40±1.39 
S.No PARAMETRIC  INDEPENDENT SAMPLE T TEST 
 Table analyzed  
1 Column A Vs column B Health Vs disease 
2 P value 0.129 
3 Exact or approximate p value Gaussian approximation 
4 P value summary Not significant 
5 On or two tailed p value Two tailed 
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Table:2a  - Relative expression of Ang 2 in health and disease 
 
 
   
Table:2b Fold change of Ang 2  in disease over health 
 
 
 
  
 
 
 
 
GROUP ct Ang 2 ct GAPDH Δct MEAN ct 
  
  
 
  
  
  
HEALTH 
33.43 23.50 9.93   
  
  
  
6.592 
35.59 25.50 10.09 
31.20 25.14 6.06 
25.84 22.50 3.33 
NA 24.34 NA 
25.10 23.57 1.52 
31.05 22.05 9.06 
27.24 21.68 5.55 
NA 23.22 NA 
31.95 24.75 7.20 
GROUP ct Ang 2 ct GAPDH Δct MEAN ct 
  
  
  
  
  
     DISEASE 
30.11 18.75 11.36   
  
  
  
  
7.683 
NA 31.45 NA 
32.31 25.29 7.01 
27.94 25.95 1.98 
33.66 24.51 9.14 
34.09 24.74 9.35 
NA 30.05 NA 
NA 24.15 NA 
NA 26.19 NA 
31.15 23.89 7.26 
GROUP MEAN Δct FOLD 
CHANGE 
DISEASE 7.683±3.31 
-1.091 
HEALTH 6.592±3.94 
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Tables: 2c -Statistical  analysis of Ang 2 
 
S.No                    PARAMETRIC INDEPENDENT SAMPLE T TEST 
 Table analyzed  
1 Column A Vs column B Health Vs disease 
2 P value 0.934 
3 Exact or approximate p value Gaussian approximation 
4 P value summary Not significant 
5 On or two tailed p value Two tailed 
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Table: 3a- Relative expression of HGF in health and disease 
 
 
 
 
 
GROUP ct HGF ct GAPDH Δct MEAN 
ct 
  
  
  
  
HEALTH 
NA 23.50 NA   
  
  
  
4.898 
28.13 25.50 2.62 
31.42 25.14 6.28 
26.23 22.50 3.73 
27.73 24.34 3.38 
30.83 23.57 7.26 
26.12 22.05 4.07 
33.08 21.68 11.47 
36.20 23.22 12.98 
NA 24.75 NA 
 
GROUP ct HGF ct GAPDH Δct 
MEAN 
ct 
  
  
  
  
     
DISEASE 
24.56 18.75 5.81   
  
  
  
          
6.473 
NA 31.45 NA 
29.36 25.29 4.07 
29.92 25.95 3.96 
34.34 24.51 9.82 
28.66 24.74 3.92 
NA 30.05 NA 
25.21 24.15 1.06 
28.76 26.19 2.57 
31.87 23.89 7.98 
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Table: 3b- Fold change of HGF  in disease over health 
 
GROUP MEAN Δct Fold change 
DISEASE 4.898±3.72 
1.574 
HEALTH 6.473±3.01 
   
 
Table: 3c- Statistical   analysis of HGF  
S.No PARAMETRIC INDEPENDENT SAMPLE T TEST 
 Table analyzed  
1 Column A Vs column B Health Vs disease 
2 P value 0.899 
3 Exact or approximate p value Gaussian approximation 
4 P value summary Not significant 
5 On or two tailed p value Two tailed 
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EXPRESSION OF Ang 1 GENE IN PERIODONTAL HEALTH AND 
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GRAPH: 2  BAR GRAPH SHOWING THE FOLD CHANGE 
EXPRESSION OF Ang 2 GENE IN PERIODONTAL HEALTH AND 
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DISCUSSION 
Periodontal diseases are a group of inflammatory conditions that result 
in the destruction of the supporting structures of the tooth. The changes in the 
vascularity of the periodontal connective tissues in untreated advanced 
periodontitis may be, in part, a consequence of altered expression of 
angiogenic activity by the epithelium.
22
  Studies using animal models of 
periodontitis, tissue from gingivitis and treated human periodontitis have 
documented the highly vascular nature of the lesion.
125 
Angiogenesis refers to the process of creation of new blood vessels 
from pre-existing blood vessels. Soluble growth factors, adhesion molecules, 
proteases, as well as the extracellular matrix have been shown to interact 
spatially and temporally to coordinate the formation of new blood vessels.  
These factors are categorized as pro angiogenic and anti angiogenic factors, 
depending on its stimulatory and inhibitory functions.
91 
The proangiogenic factors include VEGF-family, FGF-family, 
Angiopoietin 1, Angiopoietin 2, PDGF, TGF-β, TNF-α, Angiogenin, 
Angiotropin, HGF, Integrins etc. The anti angiogenic factors are Angiostatin, 
Endostatin, PEDF etc.
110 
           Studies have shown that angiogenesis plays a vital role in various 
chronic inflammatory conditions  viz Diabetes, Rheumatoid arthritis, psoriasis, 
systemic sclerosis, osteoradionecrosis, periodontal diseases etc.110    
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Angiogenesis is a prominent feature in both inflammation and healing 
of periodontal diseases, but its role in either promoting the progression of 
disease or the healing of periodontal lesion is still unclear. Several studies 
have shown that proangiogenic factors such as VEGF and FGF are involved in 
the process of inflammation in chronic periodontitis.
34,48
 As there is a paucity 
of literature on the role of the various angiogenic factors  in  periodontal 
disease conditions, this study was undertaken to evaluate if there is any 
evidence of Ang 1, Ang 2 and HGF in periodontal disease based on previous 
reports that the proangiogenic factors play a role in vascular turnover and 
remodeling in chronic periodontitis.
67
  
Ang 1, Ang 2 and HGF were chosen in this study for the following reasons,   
  Ang 1 triggers signaling pathways of Tie2 through their interaction in 
endothelial cell, and thereby promoting angiogenesis.   Angiopoietin 2, 
acts as a natural antagonist for Tie2 that disrupts the process of 
angiogenesis. Thus Ang 1 acts as an agonist and Ang 2 its antagonist.  
  The presence of elevated levels of HGF in GCF has been well 
established but its significance in diseased tissues has not been 
recorded yet. Thus this study strives to evaluate the levels of these 
proangiogenic factors in gingival tissues of health and disease. 
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The patients enrolled in this study were divided into 2 groups;  
Group A (periodontally healthy) consisted of patients with no signs of 
periodontal disease as determined by a probing depth of ≤3mm with no 
clinical attachment loss and bleeding on probing. Healthy gingival tissue 
samples were obtained from patients who reported for crown lengthening 
procedures for restorative purpose, with no signs of inflammation. 
Group B (periodontally diseased) consisted of patients with advanced 
(moderate to severe) periodontitis as per the AAP 1999 classification. 
Diseased tissue samples were obtained from patients undergoing Modified 
Widman Flap procedure. 
       The gingival samples were then stored in RNAlater®. It is an aqueous, 
non-toxic storage reagent that rapidly permeates the tissues to stabilize and 
protect cellular RNA and DNA in situ in unfrozen specimens. It has the 
advantage of preserving tissue integrity while preventing RNA degradation.
67 
Gingival tissues were homogenized, total RNA extraction done by 
SWIFT RNA isolation protocol and conversion to cDNA was done using 
standardized protocols. 
           Real time RT-PCR was then carried out, where the amplification of a 
DNA sequence is combined with a detection of thee amplified products during 
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each reaction cycle-in other words, in real time. It is a more sensitive and less 
time consuming quantitative method of measuring gene expression.      
           Real time RT-PCR analysis was carried out to evaluate the mRNA 
expression levels of Ang 1, Ang 2 and HGF in periodontal health and disease 
using SYBR® Premix with known primer sequences for Ang 1, Ang 2 and 
HGF. 
Comparative ct method was used to compare the expression levels of a 
gene in health versus diseased samples. Relative quantification is a technique 
used to analyze changes in gene expression in a given sample relative to a 
reference sample (such as an untreated control sample). The difference in the 
gene expression was expressed in terms of fold change as per previous 
literature.
30
   
            The results of the present study showed the mRNA/gene expression of 
Ang 1 in periodontal health and disease with a fold change of 3.68 times in 
disease when compared to health. But this increase was not statistically 
significant. Likewise, Ang 2 gene was also expressed in both health and 
disease with a 1.09 fold decrease in disease when compared to health which 
was not statistically significant. The gene expression of HGF was increased in 
disease by 1.574 fold over health, which was statistically insignificant. 
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Dysregulation of angiogenesis has been often associated with many 
chronic inflammatory lesions of the oral cavity including the periodontium. 
Previous reports by Yuan et al have suggested that Ang 1, Ang 2 undergo 
changes in pyogenic granuloma.
123
 Our results are in agreement with these 
studies. Etiopathogenic relevance of Ang 1, Ang 2 to the progression of 
periodontal disease is not well established. However, increased vascular 
response in the active phase of disease and neovascularization during response 
to phase 1 are well documented.
22,36 
 Vascular  events that happen in the 
episodic phases of periodontal diseases are not  yet well established.  
        The samples in our study have been obtained following phase 1 
therapy. As a result, it may be expected that the active inflammatory phase of 
periodontal disease might have subsided and the healing tissue response may 
have been characterized by fibrosis. Previous literature has shown that Ang 1 
may be liberated among other cells by the inflammatory monocytes, 
macrophages etc.
59 
The macrophages are not only important for                            
pro-inflammatory changes, but also for the matrix turnover that may be 
expected following phase 1 therapy. We therefore hypothesize that the 
increased levels of Ang 1 may be due to the macrophagic infiltration into the 
gingiva. 
Ang 2 on the other hand, showed a statistically insignificant 
downregulation, probably as a result of counter-balancing mechanism to the 
increased Ang 1 levels in the gingival tissues. Ang 2 production has not been 
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well documented from the inflammatory cells as much as Ang 1. This could be 
the reason for the differential expression of Ang 1, Ang 2 observed in our 
samples. 
Taken together, our results suggest that there is a dysregulation of                 
Ang 1, Ang 2 proteins in periodontal disease. Although the exact pathogenic 
mechanisms are difficult to establish from this study, it is speculated that these 
changes may affect the periodontium in the following ways: 
1. Neovascularization has been reported to be initiated from the renewal 
of microcirculation from the venous end through macrophagic 
liberation of Ang 1. It is therefore possible that the venous stasis 
observed in edematous gingival tissues could be a result of   
dysregulation of Ang 1and Ang 2. 
2. Dysregulation of Ang 1 and Ang 2 could lead to impaired 
angiogenesis. This impairment could be an important reason for non- 
resolution of chronic inflammation in periodontal disease. The 
importance of vascularity in periodontal disease ensuring the supply of 
cells, matrix components and signaling molecules has been previously 
documented.
36
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HGF is a known mitogen, motogen and scatter factor. The upregulation 
of HGF in periodontal disease is in line with previous literature.
78,82,83,84,95,117
  
HGF is associated with the proliferation and apical migration of epithelial 
cells. The presence of c-Met receptors in the junctional epithelium, which help 
this process has been well documented.
73,80 
 The samples obtained in our study 
would have shown an increased level of HGF as a result of disease process 
due to the apical migration of junctional epithelium. The increase in the level 
of HGF could also possibly be due the healing response as a result of phase1 
therapy as reepithelization occurs in the junctional epithelium of the healing 
periodontium.   
The involvement of HGF in the angiogenic process is also well  
documented.
13,55,83,104,115
 There is clear evidence for the importance of 
angiogenesis in the process of wound healing.
42,73,85,104
 Thus, our study is in 
agreement with  previous literature that have shown higher HGF in 
periodontal disease. 
         The clinical implications of the study are that HGF can be used as a 
potential therapeutic marker because of its influence on epithelial migration 
and angiogenesis both in the disease progression and in the phases of healing.  
           The limitations of this study are that a comparatively smaller sample 
size has been investigated. The fact that the samples were not obtained at the 
active phase of the disease is also a limitation of this study.   
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  Further studies targeted at elucidating the mechanism of actions of    
Ang 1, Ang 2 and HGF in the active phases of the periodontal disease with a 
considerable larger sample size could provide a deeper insight into the 
involvement in periodontal disease. 
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SUMMARY AND CONCLUSION 
 The process of angiogenesis and its importance in chronic 
inflammatory disease conditions is well established. The influence of the 
various proangiogenic markers have been identified till date and their 
involvement in the disease progression periodontitis have been confirmed.   
             This study was carried out to evaluate the gene expression of Ang 1, 
Ang 2 and HGF in periodontally healthy and diseased tissue samples.                      
20 patients who reported to the Department of Periodontics, Ragas dental 
college and Hospital were enrolled in the study. The patients were divided into                    
2 groups based on their periodontal health status, as 10 healthy and                          
10 diseased groups. Healthy tissue samples were obtained from patients who 
underwent crown lengthening procedure. Diseased tissue samples were 
obtained from patients who underwent Modified Widman flap surgery. 
Isolation of the total RNA was done, real time reverse transcription 
polymerization chain reaction was carried out to evaluate the gene expression 
of Ang 1, Ang 2 and HGF.  
The results demonstrated an upregulation of Ang 1 gene with a fold 
change of 3.68 and HGF gene 1.574 fold in patients with periodontal disease 
when compared with the periodontally healthy group, whereas there was a 
down regulation of Ang 2 gene with a 1.091 fold decrease in periodontal 
disease group, which explains the agonist and antagonist nature of Ang 1 and 
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Ang 2 respectively in inflammatory conditions. However further studies with a 
larger sample size and the collection of tissue samples during the active phase 
of disease is required to substantiate the role of these cells in the disease 
progression of periodontium. 
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ANNEXURE I 
 
INFORMED CONSENT 
DEPARTMENT OF PERIODONTICS 
 
 1) NAME: 
2) AGE & SEX: 
3) OCCUPATION: 
4) INCOME: 
5) ADDRESS: 
6) CONTACT NO: 
7) BIOPSY: 
            a) Type: 
            b) Nature of specimen: 
8) CLINICAL DETAILS: 
            a) Site: 
           b) Colour: 
          c) Consistency: 
          d) Size: 
9) PROVISIONAL DIAGNOSIS: 
10) PATIENT CONSENT:  
   
 
Annexures 
 
I have been informed about the surgical procedure for removal of 
gingival tissue while performing periodontal surgery that will not have any 
determined effect on my healing soft tissue. The tissue obtained will be used 
for research purpose only, the result which will be informed to my request. I 
henceforth give my consent for the above procedure.  
  
PATIENT SIGN                  
 
DOCTOR SIGN 
  
                                                                                                                                                
                                                                                                                         
HOD SIGN 
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